Increased risk of hypoglycemia, including severe hypoglycemia, in patients receiving tirzepatide in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin
How does the PlexusDx Precision Peptide Genetic Test personalize my treatment
Broader clinical trial data suggests that approximately 10% of patients across all indications and doses may discontinue semaglutide due to GI complaints, which is comparable to or slightly higher than other GLP-1 receptor agonists
The primary outcome was clinical response at week 8 defined as decrease in total MS of at least 3 points and 30% with decrease in RBS of at least 1 point or absolute RBS of 0 or 1, while secondary outcomes included clinical remission rate at week 8, mucosal healing rate at week 8, and changes from baseline in total MS, partial MS, modified Riley score, and various biomarkers including C-reactive protein, albumin, and calprotectin at multiple timepoints through week 24
For some, this may manifest as a decrease in libido or a lack of motivation, which can create a feedback loop that reinforces the compulsive behavior
[41] explained the liraglutide- related improvement of dyslipidemia by enhanced satiety sensation and weight loss
